T1	HMM 189 228	angiogenesis-targeted sunitinib therapy
T2	HMM 574 590	overall survival
T3	HMM 627 658	progression-free survival (PFS)
T4	HMM 957 966	median OS
T5	HMM 1127 1130	PFS
T6	HMM 1277 1341	Toxicity and rates of discontinuations because of adverse events
T7	HMM 1453 1460	fatigue
T8	HMM 1472 1480	asthenia
T9	HMM 1496 1514	hand-foot syndrome
T10	HMM 1564 1589	hematologic abnormalities
T11	HMM 1595 1606	lymphopenia
T12	HMM 1620 1626	anemia
T13	HMM 1642 1653	neutropenia
T14	HMM 1734 1736	OS
